NCT06289504

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how CagriSema affects the blood levels of atorvastatin and warfarin. The study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking CagriSema and if this changes after the participant has taken CagriSema. The study will also investigate the effect of warfarin before and after the participant takes CagriSema and assess if the injection site affects the level of CagriSema in the blood. The study will last for about 8 months.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Cagrilintide	Cagrilintide will be administered subcutaneously once weekly.
DRUG	Semaglutide	Semaglutide will be administered subcutaneously once weekly.
DRUG	Atorvastatin	Atorvastatin will be administered as a single dose orally 2 times during the study.
DRUG	Warfarin	Warfarin will be administered as a single dose orally 2 times during the study.

Timeline

• Start date: 2024-02-27
• Primary completion: 2024-10-16
• Completion: 2024-11-15
• First posted: 2024-03-04
• Last updated: 2025-05-11

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study